A case of curatively resected gastric wall implantation of pancreatic cancer caused by endoscopic ultrasound-guided fine-needle aspiration

An 87-year-old woman with a pancreatic mass was referred to our hospital for treatment. Contrast-enhanced computed tomography (CT) revealed a 25-mm-diameter mass with cystic changes in the body of the pancreas (Fig. 1a). Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was performed using a 22-gauge needle (Fig. 1b), and cytohistological examination revealed a squamous cell carcinoma. Accordingly, distal pancreatectomy was performed, and the lesion was diagnosed as an adenosquamous carcinoma of the pancreas with T2N0M0 classification. The patient rejected adjuvant chemotherapy but consented to routine blood tests and contrast-enhanced CT every 3 months to monitor for recurrence.

At 19 months after surgery, the tumor marker CA19-9 level had increased within the normal range. A contrast-enhanced CT showed a 20-mm-diameter mass with cystic changes and features similar to those of the resected pancreatic mass in the posterior stomach wall, despite the absence of other metastatic lesions (Fig. 2a). A second EUS-FNA was performed (Fig. 2b) and the lesion was identified as another squamous cell carcinoma. Positron emission tomography showed no other metastases (Fig. 2c), and the patient underwent partial gastrectomy. The lesion was diagnosed definitively as a needle-track implantation caused by EUS-FNA, as it arose from the gastric wall subserosa (Fig. 3a) and its histology was identical to that of the squamous cell carcinoma within the primary pancreatic carcinoma (Fig. 3b, c). No recurrence was observed for 16 months.

To our knowledge, this is the first report of a gastric wall metastasis of pancreatic cancer caused by EUS-FNA with pathological proof of needle-track implantation. Although such a mechanism of metastasis is rare [1–4], it seems mandatory that implantation is detected before metastases occur in order to ensure radical cure. Therefore, planned examinations and cautious interpretation of blood tests and images may be essential, even following curative resection of early-stage pancreatic cancer.

Endoscopy_UCTN_Code_CPL_1AL_2AD

Competing interests: None
References


Bibliography

DOI http://dx.doi.org/10.1055/s-0034-1377592
Endoscopy 2015; 47: E198–E199
© Georg Thieme Verlag KG
Stuttgart · New York
ISSN 0013-726X

Corresponding author
Tsuyoshi Hayashi, MD
Department of Medical Oncology and Hematology
Sapporo Medical University School of Medicine
South-1, West-16, Chuo-ku
Sapporo 060-8543
Hokkaido
Japan
Fax: +81-11-6127087
thayashi69@sapmed.ac.jp

Akira Sakurada1, Tsuyoshi Hayashi1, Michihiro Ono1, Hirotoshi Ishiwatari1, Jiro Ogino2, Yasutoshi Kimura3, Junji Kato1

1 Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan
2 Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
3 Department of Surgery, Surgical Oncology and Science, Sapporo Medical University School of Medicine, Sapporo, Japan

Fig. 3 Histological analysis.

a Gastric metastasis (hematoxylin and eosin [H&E], loupe). b Gastric metastasis (H&E × 400).
c The primary pancreatic lesion (H&E × 400).